Piper Sandler Maintains Neutral on Core Laboratories, Raises Price Target to $21
Portfolio Pulse from richadhand@benzinga.com
Piper Sandler analyst Luke Lemoine maintains a Neutral rating on Core Laboratories (NYSE:CLB) and raises the price target from $19 to $21.
July 31, 2023 | 4:28 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Piper Sandler maintains a Neutral rating on Core Laboratories and raises the price target from $19 to $21.
The news directly pertains to Core Laboratories as Piper Sandler maintains a Neutral rating on the company and raises the price target. This suggests that the analyst sees potential in the company but also acknowledges risks. This could lead to a neutral impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100